Peter is Co-founder and Chief Executive Officer of Greywolf and has over 13 years of experience in biomedical research leading drug discovery projects in immuno-oncology, rare genetic diseases and neurodegeneration. In his most recent role at Vertex Pharmaceuticals, he led drug discovery projects, had responsibility for leading a number of target identification teams that led to multiple novel drug discovery projects and was involved in delivering clinical drug candidates. He also pioneered the development of complex neurological assays suitable for assessing the functional impact of optimized compounds. Prior to Vertex, Peter was an MRC Research Fellow investigating the pathophysiology and underlying mechanisms of neurodegeneration and publishing multiple first and co-author publications. Peter holds a PhD in Biochemistry and Molecular Genetics from the University of Bristol and a BSc in Biochemistry.